Quantum Genomics (Quantum Genomics) Debt-to-Equity : 0.83 (As of Dec. 2022)

View and export this data going back to 2017. Start your Free Trial

What is Quantum Genomics Debt-to-Equity?

Quantum Genomics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2022 was $0.00 Mil. Quantum Genomics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2022 was $3.21 Mil. Quantum Genomics's Total Stockholders Equity for the quarter that ended in Dec. 2022 was $3.86 Mil. Quantum Genomics's debt to equity for the quarter that ended in Dec. 2022 was 0.83.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Quantum Genomics's Debt-to-Equity or its related term are showing as below:

QNNTF's Debt-to-Equity is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.145
* Ranked among companies with meaningful Debt-to-Equity only.

Quantum Genomics Debt-to-Equity Historical Data

The historical data trend for Quantum Genomics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Quantum Genomics Debt-to-Equity Chart

Quantum Genomics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-Equity

Get a 7-Day Free Trial

0.26

0.83

Quantum Genomics Semi-Annual Data
	Jun13	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22
Debt-to-Equity	Get a 7-Day Free Trial															-	0.14	0.26	0.22	0.83

Competitive Comparison of Quantum Genomics's Debt-to-Equity

For the Biotechnology subindustry, Quantum Genomics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Quantum Genomics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Quantum Genomics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Quantum Genomics's Debt-to-Equity falls into.

Quantum Genomics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Quantum Genomics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	3.214)	/	3.864
	=	0.83

Quantum Genomics's Debt to Equity Ratio for the quarter that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	3.214)	/	3.864
	=	0.83

Quantum Genomics (OTCPK:QNNTF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Quantum Genomics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Quantum Genomics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Quantum Genomics (Quantum Genomics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Quantum Genomics (OTCPK:QNNTF) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

ALQGC:France 2QG:Germany

Address

33, Rue Marbeuf, Paris, FRA, 75008

Website

https://quantum-genomics.com

Quantum Genomics is a biopharmaceutical company engaged in developing new products for unmet needs in the field of cardiovascular diseases, high blood pressure, and heart failure. The company products include firibastat, QGC006, QGC011, and others.